SCHEMBL1991763

SCHEMBL1991763

C=C(C)C(=O)OCCOCCCCOCCOC(=O)C(=C)C

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.70
TSHR P16473 7/20 0.62
HTT P42858 2/20 0.46
POLB P06746 1/20 0.46
APEX1 P27695 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 7/20 0.41
TP53 P04637 2/20 0.40
HIF1A Q16665 2/20 0.40
HSD17B10 Q99714 1/20 0.40
CES2 O00748 1/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPT P10636 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9464153 0.98 THRB (0.68) THRBTSHRHTTPOLBAPEX1
SCHEMBL14706828 0.98 THRB (0.68) THRBTSHRHTTPOLBAPEX1
SCHEMBL9568827 0.96 THRB (0.70) THRBTSHRHTTPOLBAPEX1
SCHEMBL2742411 0.96 THRB (0.70) THRBTSHRHTTPOLBAPEX1
SCHEMBL3103061 0.94 TSHR (0.71) THRBTSHRHTTPOLBAPEX1
SCHEMBL9066861 0.93 TSHR (0.70) THRBTSHRHTTPOLBAPEX1
SCHEMBL9066134 0.93 TSHR (0.70) THRBTSHRHTTPOLBAPEX1
SCHEMBL9066855 0.93 TSHR (0.70) THRBTSHRHTTPOLBAPEX1
SCHEMBL9066211 0.93 TSHR (0.70) THRBTSHRHTTPOLBAPEX1
SCHEMBL8850814 0.93 TSHR (0.70) THRBTSHRHTTPOLBAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970443-B2 Crosslinking agent compound and superabsorbent polymer prepared by using the same LG CHEM, LTD. (KR) 2024-04-30 US disclosed
EP-3725762-B1 NOVEL CROSSLINKER COMPOUND AND SUPERABSORBENT POLYMER PREPARED USING SAME LG CHEMICAL LTD (KR) 2024-02-28 EP disclosed
EP-3540001-B1 HIGHLY ABSORPTIVE RESIN AND METHOD FOR PRODUCING SAME LG CHEMICAL LTD (KR) 2023-01-04 EP disclosed
US-20200369595-A1 Novel Crosslinking Agent Compound and Superabsorbent Polymer Prepared by Using the Same LG CHEM, LTD. (KR) 2020-11-26 US disclosed
EP-3725762-A1 NOVEL CROSSLINKER COMPOUND AND SUPERABSORBENT POLYMER PREPARED USING SAME LG CHEM, LTD. (KR) 2020-10-21 EP disclosed
US-20190344243-A1 Superabsorbent Polymer and Preparation Method Thereof LG CHEM, LTD. (KR) 2019-11-14 US disclosed
EP-3540001-A1 HIGHLY ABSORPTIVE RESIN AND METHOD FOR PRODUCING SAME LG Chem, Ltd. (KR) 2019-09-18 EP disclosed
US-20140194524-A1 Methods for Treating Alzheimer's Disease COGNITION PHARMACEUTICALS, LLC (US) 2014-07-10 US disclosed
EP-1635851-B1 METHODS FOR TREATING COGNITIVE IMPAIRMENT AND IMPROVING COGNITION COGNITION PHARMACEUTICALS LLC (US) 2013-10-16 EP disclosed
US-20130231395-A1 METHODS FOR TREATING ALZHEIMER'S DISEASE COGNITION PHARMACEUTICALS, LLC (US) 2013-09-05 US disclosed
US-20030229122-A1 Use of methylphenidate compounds to enhance memory SENTION, INC. 2003-12-11 US disclosed
US-20030119884-A1 Methods and compositions for regulating memory consolidation PANMEDIX, INC. 2003-06-26 US disclosed
EP-1315495-A2 USE OF THREO-METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY Sention, Inc. (US) 2003-06-04 EP disclosed
US-20020132793-A1 Use of methylphenidate compounds to enhance memory SENTION INC. 2002-09-19 US disclosed
US-20020115725-A1 Methods and compositions for regulating memory consolidation PRIESTLEY, KATHERINE (GB) 2002-08-22 US disclosed
US-20020103162-A1 Use of threo-methylphenidate compounds to enhance memory SENTION, INC. 2002-08-01 US disclosed
WO-2002039998-A2 METHODS AND COMPOSITIONS FOR REGULATING MEMORY CONSOLIDATION SENTION, INC. (US) 2002-05-23 WO disclosed
WO-2002017920-A2 USE OF METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY SENTION, INC (US) 2002-03-07 WO disclosed
WO-2002017919-A2 USE OF THREO-METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY SENTION, INC. (US) 2002-03-07 WO disclosed
EP-0922709-A1 PROCESS FOR PRODUCING (METH)ACRYLATE DERIVATIVES NOF CORPORATION (JP) 1999-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194524-A1 Methods for Treating Alzheimer's Disease CHAT, ACHE, PNMT THRB 2687/4885TSHR 4699/4885HTT 36/4885
US-20020132793-A1 Use of methylphenidate compounds to enhance memory PNMT, CHAT, SLC6A3 THRB 3199/4885TSHR 4167/4885HTT 843/4885
US-20020103162-A1 Use of threo-methylphenidate compounds to enhance memory SLC6A3, SLC6A2, PNMT THRB 706/4885TSHR 2465/4885HTT 684/4885
US-11970443-B2 Crosslinking agent compound and superabsorbent polymer prepared by using the same NOTUM, PCNA, UROD THRB 4882/4885TSHR 4474/4885HTT 3975/4885
US-20030229122-A1 Use of methylphenidate compounds to enhance memory PNMT, GRIN3B, GRIN3A THRB 2079/4885TSHR 3560/4885HTT 605/4885
US-20130231395-A1 METHODS FOR TREATING ALZHEIMER'S DISEASE CHAT, ACHE, PNMT THRB 2687/4885TSHR 4699/4885HTT 36/4885
US-20030119884-A1 Methods and compositions for regulating memory consolidation BDNF, CHAT, DCX THRB 4401/4885TSHR 4650/4885HTT 1554/4885
US-20020115725-A1 Methods and compositions for regulating memory consolidation BDNF, CHAT, GAP43 THRB 3535/4885TSHR 4489/4885HTT 1533/4885
US-20200369595-A1 Novel Crosslinking Agent Compound and Superabsorbent Polymer Prepared by Using the Same NOTUM, UROD, STOM THRB 4883/4885TSHR 4495/4885HTT 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.